Researchers at the University of Illinois Urbana-Champaign reported that in vivo CRISPR base editing can reduce toxic protein burden and neurologic symptoms in a mouse model of Huntington’s disease. The approach reframes treatment by altering how the mutant HTT gene is processed, rather than fully turning the gene off. In the Nature Biomedical Engineering work, the team used base editors engineered to disrupt the splice acceptor of HTT exon 13, aiming to generate proteolysis-resistant HTT isoforms and reduce formation of toxic N-terminal fragments linked to neurodegeneration. The preclinical results emphasize disease biology tied to protein cleavage and downstream toxicity, supporting a precision variant of genome editing intended to preserve gene function while modifying the harmful processing step. As in vivo editing moves toward clinical translation, the key will be delivery, durability, and off-target controls outside the mouse model context.